|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:fulvestrant
|
|
gptkbp:activities
|
CD K4/6 inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2015
gptkb:FDA
|
|
gptkbp:brand
|
Ibrance
|
|
gptkbp:can_be_used_with
|
gptkb:letrozole
gptkb:fulvestrant
gptkb:anastrozole
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase III
first-line therapy
second-line therapy
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Pfizer
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
28 days on, 14 days off
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
palbociclib
|
|
gptkbp:indication
|
gptkb:hormone_receptor-positive_breast_cancer
|
|
gptkbp:ingredients
|
C23 H29 N5 O2
|
|
gptkbp:interacts_with
|
gptkb:beer
|
|
gptkbp:invention
|
2026
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
approximately 29 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
CY P3 A4
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
|
|
gptkbp:population
|
postmenopausal women
|
|
gptkbp:research
|
PALOMA-1
PALOMA-2
PALOMA-3
PALOMA-4
PALOMA-5
|
|
gptkbp:research_focus
|
combination therapies
|
|
gptkbp:safety_features
|
monitor blood counts
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
diarrhea
liver enzyme elevation
hair loss
thrombocytopenia
infection risk
pulmonary embolism
neutropenia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:cyclin-dependent_kinase_6
cyclin-dependent kinase 4
|
|
gptkbp:weight
|
393.51 g/mol
|